Preparing to expand South American business next year

AI medical imaging analysis company AIDOT Co., Ltd. (AIDOT, CEO Jaehoon Jung) is moving to fully target the Latin American market, led by its AI-based digital colposcope (cervical magnification examination device) “Cerviray AI.”

Cerviray scans the cervix to automatically highlight areas suspected of lesions and provides four-level lesion classification results as a clinical decision support system (CDSS) device.

In Mexico, the company will first conduct demonstrations primarily at private medical institutions in Mexico City, and plans to expand the scope of deployment to major metropolitan areas such as Monterrey and Guadalajara.

In Chile, it plans to enter the market centered on Santiago. In both countries, the company intends to gradually broaden the deployment range to surrounding regions with lower accessibility, expanding the market step by step.

A representative from a local distribution partner in Mexico said, “At the beginning, it was necessary to address clinicians’ concerns about adopting new AI-based technology.” They added, “At first there were worries about using AI, but after actually using it, more and more people are responding positively, saying it helps support the clinical workflow.”

According to on-site feedback, Cerviray is evaluated as convenient to introduce and operate because, compared with existing equipment, it does not require separate installation, and does not need complex wiring or additional space configuration.

Cervical cancer is a disease for which regular screening and early detection are crucial. AIDOT stated, “We hope Cerviray will reduce clinicians’ burden and help more women gain timely access to screening opportunities.”

Through this demonstration, AIDOT plans to further refine its localization strategy tailored to each country’s medical environment and operational processes, and to organize partner-based distribution and service systems to drive full-scale business expansion.

Key features of Cerviray AI include:

• On-device AI interpretation (no internet required; immediate results)

• MFDS (Korea’s Ministry of Food and Drug Safety) approval as a Class III AI medical device

• Provision of lesion classification results (e.g., Normal / CIN1 / CIN2·3 / CIN3+)

• Detailed lesion detection box 표시/display

Korea Economic TV / 2026-01-16 / Deputy Bureau Chief Jaejun Yang